compounded semaglutide fda warning november 2025 🚨 Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these UPDATE: Two Considerations When Prescribing

Published research provides context for understanding transdermal delivery considerations

Side Effects Compared Both drugs share the same dominant side effect profile: gastrointestinal, dose-related, and usually worst early in treatment

Li, L.-H., Chen, H.-B., Zhang, L.-P., Wang, Z.-W

Push the air into the vial of medication

The Big Picture The journey into understanding GLP-1s has unveiled a profound scientific truth: their ability to reduce inflammation is not merely a consequence of weight loss, but a direct and independent action that precedes significant changes on the scale

retatrutide has no UK marketing authorisation, BNF listing, or NICE appraisal, and no guidelines exist for their combined use